- PROFESSOR | Environmental Medicine & Public Health
- PROFESSOR | Obstetrics, Gynecology and Reproductive Science
Dr. Swan has worked for over twenty-five years to understand the threats posed by chemicals to our environment and our health, and, when necessary, to develop new paradigms to assess their risks. Of most concern to Dr. Swan are the chemicals that our bodies can confuse with its own hormones (the “endocrine disrupting” chemicals). At the Mount Sinai School of Medicine, Dept of Preventive Medicine, Dr. Swan is working with a wide range of collaborators, including epidemiologists, biostatisticians, toxicologists, geneticists and systems biologists, to conduct studies and develop methods to evaluate the risks from such chemicals — methods that are sensitive enough to tease out the often subtle health effects of complex mixtures.
Hay-Schmidt A, Finkielman OT, Jensen BA, Høgsbro CF, Bak Holm J, Johansen KH, Jensen TK, Andrade AM, Swan SH, Bornehag CG, Brunak S, Jegou B, Kristiansen K, Kristensen DM. Prenatal exposure to paracetamol/acetaminophen and precursor aniline impairs masculinisation of male brain and behaviour. Reproduction (Cambridge, England) 2017 Aug; 154(2).
Barrett ES, Sathyanarayana S, Mbowe O, Thurston SW, Redmon JB, Nguyen RH, Swan SH. First-Trimester Urinary Bisphenol A Concentration in Relation to Anogenital Distance, an Androgen-Sensitive Measure of Reproductive Development, in Infant Girls. Environmental health perspectives 2017 Jul; 125(7).
Sathyanarayana S, Butts S, Wang C, Barrett E, Nguyen R, Schwartz SM, Haaland W, Swan SH. Early Prenatal Phthalate Exposure, Sex Steroid Hormones, and Birth Outcomes. The Journal of clinical endocrinology and metabolism 2017 Jun; 102(6).
Sathyanarayana S, Grady R, Barrett ES, Redmon B, Nguyen RH, Barthold JS, Bush NR, Swan SH. First trimester phthalate exposure and male newborn genital anomalies. Environmental research 2016 Nov; 151.
Kita DH, Meyer KB, Venturelli AC, Adams R, Machado DL, Morais RN, Swan SH, Gennings C, Martino-Andrade AJ. Manipulation of pre and postnatal androgen environments and anogenital distance in rats. Toxicology 2016 Aug; 368-369.
Sathyanarayana S, Barrett E, Nguyen R, Redmon B, Haaland W, Swan SH. First Trimester Phthalate Exposure and Infant Birth Weight in the Infant Development and Environment Study. International journal of environmental research and public health 2016 Sep; 13(10).
Sathyanarayana S, Grady R, Barrett ES, Redmon B, Nguyen RH, Barthold JS, Bush NR, Swan SH. First trimester phthalate exposure and male newborn genital anomalies. Environmental research 2016 Aug;.
Swan SH, Sathyanarayana S, Barrett ES, Janssen S, Liu F, Nguyen RH, Redmon JB. First trimester phthalate exposure and anogenital distance in newborns. Human reproduction (Oxford, England) 2015 Apr; 30(4).
Bornehag CG, Carlstedt F, Jönsson BA, Lindh CH, Jensen TK, Bodin A, Jonsson C, Janson S, Swan SH. Prenatal Phthalate Exposures and Anogenital Distance in Swedish Boys. Environmental health perspectives 2015 Jan;.
Evans SF, Kobrosly RW, Barrett ES, Thurston SW, Calafat AM, Weiss B, Stahlhut R, Yolton K, Swan SH. Prenatal Bisphenol A Exposure and maternally reported behavior in boys and girls. Neurotoxicology 2014 Oct;.
Kobrosly RW, Evans S, Miodovnik A, Barrett ES, Thurston SW, Calafat AM, Swan SH. Prenatal phthalate exposures and neurobehavioral development scores in boys and girls at 6-10 years of age. Environmental health perspectives 2014 May; 122(5).
Mendiola J, Jørgensen N, Andersson AM, Stahlhut RW, Liu F, Swan SH. Reproductive parameters in young men living in Rochester, New York. Fertility and sterility 2014 Apr; 101(4).
Swan SH, Liu F, Hines M, Kruse RL, Wang C, Redmon JB, Sparks A, Weiss B. Prenatal phthalate exposure and reduced masculine play in boys. International journal of andrology 2010 Apr; 33(2).
Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, Mao CS, Redmon JB, Ternand CL, Sullivan S, Teague JL. Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environmental health perspectives 2005 Aug; 113(8).
Swan SH, Kruse RL, Liu F, Barr DB, Drobnis EZ, Redmon JB, Wang C, Brazil C, Overstreet JW. Semen quality in relation to biomarkers of pesticide exposure. Environmental health perspectives 2003 Sep; 111(12).
Swan SH, Brazil C, Drobnis EZ, Liu F, Kruse RL, Hatch M, Redmon JB, Wang C, Overstreet JW. Geographic differences in semen quality of fertile U.S. males. Environmental health perspectives 2003 Apr; 111(4).
Swan SH, Elkin EP, Fenster L. The question of declining sperm density revisited: an analysis of 101 studies published 1934-1996. Environmental health perspectives 2000 Oct; 108(10).
Swan SH, Elkin EP, Fenster L. Have sperm densities declined? A reanalysis of global trend data. Environmental health perspectives 1997 Nov; 105(11).
Beaumont JJ, Swan SH, Hammond SK, Samuels SJ, Green RS, Hallock MF, Dominguez C, Boyd P, Schenker MB. Historical cohort investigation of spontaneous abortion in the Semiconductor Health Study: epidemiologic methods and analyses of risk in fabrication overall and in fabrication work groups. American journal of industrial medicine 1995 Dec; 28(6).
Swan SH, Beaumont JJ, Hammond SK, VonBehren J, Green RS, Hallock MF, Woskie SR, Hines CJ, Schenker MB. Historical cohort study of spontaneous abortion among fabrication workers in the Semiconductor Health Study: agent-level analysis. American journal of industrial medicine 1995 Dec; 28(6).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Swan did not report having any of the following types of financial relationships with industry during 2016 and/or 2017: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.